Novartis maps $100M R&D complex in China

Novartis is building a $100 million research center in Shanghai, another example of the growing clout that China is demonstrating in the drug development industry. The 400,000-square-foot center will be Novartis' eighth R&D complex, employing some 400 scientists. Construction is set to begin the middle of next year. Analysts said that Novartis was lining up to take advantage of a lower-cost approach to developing new therapies.

- here's the AFP report on Novartis' China plans

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.